135 related articles for article (PubMed ID: 23554843)
41. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
42. Androgen receptors in prostate cancer.
Culig Z; Klocker H; Bartsch G; Hobisch A
Endocr Relat Cancer; 2002 Sep; 9(3):155-70. PubMed ID: 12237244
[TBL] [Abstract][Full Text] [Related]
43. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
44. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
[TBL] [Abstract][Full Text] [Related]
45. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
[TBL] [Abstract][Full Text] [Related]
46. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Cancer Res; 2001 Oct; 61(20):7544-51. PubMed ID: 11606392
[TBL] [Abstract][Full Text] [Related]
47. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Bhattacharyya RS; Krishnan AV; Swami S; Feldman D
Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513
[TBL] [Abstract][Full Text] [Related]
48. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
[TBL] [Abstract][Full Text] [Related]
49. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway.
Lee SO; Lou W; Johnson CS; Trump DL; Gao AC
Prostate; 2004 Aug; 60(3):178-86. PubMed ID: 15176047
[TBL] [Abstract][Full Text] [Related]
50. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
51. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
52. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC
Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330
[TBL] [Abstract][Full Text] [Related]
53. Calreticulin expression is associated with androgen regulation of the sensitivity to calcium ionophore-induced apoptosis in LNCaP prostate cancer cells.
Zhu N; Wang Z
Cancer Res; 1999 Apr; 59(8):1896-902. PubMed ID: 10213498
[TBL] [Abstract][Full Text] [Related]
54. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6.
Debes JD; Schmidt LJ; Huang H; Tindall DJ
Cancer Res; 2002 Oct; 62(20):5632-6. PubMed ID: 12384515
[TBL] [Abstract][Full Text] [Related]
55. Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.
Terakawa T; Miyake H; Furukawa J; Ettinger SL; Gleave ME; Fujisawa M
Br J Cancer; 2009 Nov; 101(10):1731-9. PubMed ID: 19844233
[TBL] [Abstract][Full Text] [Related]
56. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
[TBL] [Abstract][Full Text] [Related]
57. Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells.
Dai B; Chen H; Guo S; Yang X; Linn DE; Sun F; Li W; Guo Z; Xu K; Kim O; Kong X; Melamed J; Qiu S; Chen H; Qiu Y
Cancer Res; 2010 Jul; 70(13):5587-96. PubMed ID: 20570899
[TBL] [Abstract][Full Text] [Related]
58. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
59. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.
Shi XB; Xue L; Zou JX; Gandour-Edwards R; Chen H; deVere White RW
Prostate; 2008 Dec; 68(16):1816-26. PubMed ID: 18780293
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
Eder IE; Hoffmann J; Rogatsch H; Schäfer G; Zopf D; Bartsch G; Klocker H
Cancer Gene Ther; 2002 Feb; 9(2):117-25. PubMed ID: 11857028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]